Glenmark Pharmaceuticals update on Phase 1 trail of Immuno-Oncology Agent GBR 1342

Conducts first-in-human, open-label study for dosing of GBR 1342

Glenmark Pharmaceuticals announced that the first patient has been dosed in a Phase 1 trial of GBR 1342 (NCT03309111), an investigational bispecific antibody. This first-in-human, open-label study's primary objective is to assess the safety and tolerability of increasing doses of GBR 1342 in multiple myeloma patients until a maximum tolerated dose is reached. Additional study objectives include assessment of biomarkers, immunogenicity and additional measures of anti-tumor activity.

Powered by Capital Market - Live News